MODERNA INC
NASDAQ: MRNA (Moderna, Inc.)
Kemas kini terakhir: 3 jam lalu53.86
-2.40 (-4.26%)
| Penutupan Terdahulu | 56.26 |
| Buka | 57.54 |
| Jumlah Dagangan | 5,545,464 |
| Purata Dagangan (3B) | 7,623,300 |
| Modal Pasaran | 21,502,846,976 |
| Harga / Jualan (P/S) | 9.75 |
| Harga / Buku (P/B) | 3.22 |
| Julat 52 Minggu |
| Margin Keuntungan | -105.67% |
| Margin Operasi (TTM) | -972.22% |
| EPS Cair (TTM) | -8.73 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -35.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.40% |
| Nisbah Semasa (MRQ) | 4.22 |
| Aliran Tunai Operasi (OCF TTM) | -3.05 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.20 B |
| Pulangan Atas Aset (ROA TTM) | -15.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Moderna, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.83 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.28% |
| % Dimiliki oleh Institusi | 73.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Capital World Investors | 31 Mar 2026 | 18,697,694 |
| Theleme Partners Llp | 31 Mar 2026 | 8,048,245 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2026 | CNBC | Hantavirus outbreak isn't another Covid pandemic – but experts say it's testing U.S. readiness |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |